Registry for people at risk of pancreatic cancer
Official title: Italian Registry of Families At Risk of Pancreatic Cancer
Run by Associazione Italiana per lo Studio del Pancreas · NCT04095195 · Data updated 2026-11-12
This study is collecting information from people at risk of pancreatic cancer due to family history or genetic factors to see if regular check-ups can help catch the disease early.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Associazione Italiana per lo Studio del Pancreas Academic / other |
| Locations | 4 sites (Rozzano, Milan and 3 other locations) |
| Status | Recruiting |
| Started | August 20, 2019 |
| Main results expected | August 20, 2044 |
| Study ends | September 20, 2045 |
| Registry record updated | January 13, 2023 |
| Trial ID | NCT04095195 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a family history of pancreatic cancer or known genetic mutations associated with increased risk.
✕Probably not a fit
Patients without a family history of pancreatic cancer or those without the specified genetic predispositions may not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to collect data on individuals with inherited risks for pancreatic cancer, including those with familial pancreatic cancer and specific genetic mutations like BRCA1 and BRCA2. Participants over 18 years old will have their family history and medical records documented, and based on their risk factors, they may undergo surveillance procedures such as Magnetic Resonance Cholangiopancreatography (MRCP) or Endoultrasonography. The goal is to improve early detection and diagnosis of pancreatic cancer or its predisposing lesions through systematic screening.
Why it matters
Potential benefit: If successful, this registry could lead to earlier diagnosis and improved survival rates for patients at high risk of pancreatic cancer.
How similar studies have gone: Other studies focusing on genetic predispositions and early detection of pancreatic cancer have shown promise, indicating that this approach is supported by previous findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria to enter the registry: * individuals with at least two relatives suffering from pancreatic cancer, with at least 1 first-degree and until the third-degree * subjects with known genetic mutation of BRCA2, BRCA1, p16, PALB2 with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer * subjects suffering from FAMMM Syndrome * subjects suffering from Peutz-Jeghers Syndrome * subjects suffering from PRSS-1- or CFTR- or SPINK-1- related pancreatitis * subjects suffering from Lynch syndrome with at least 1 first- or 2nd-degree relative suffering from pancreatic cancer Inclusion criteria to join the "radiologic follow-up": * 45 years or 10 years younger than the youngest index case of pancreatic cancer in the family for familial cases * 40 years or 5 years younger than the youngest index case of pancreatic cancer for subjects suffering from hereditary/genetic pancreatitis, Lynch syndrome, or carrying a known BRCA 1/2, PALB2, p16 genetic mutation with familiarity for pancreatic cancer * 30 years for subjects suffering from FAMMM, Peutz-Jeghers syndrome Exclusion Criteria: \- pregnancy
Where it's running
-
Istituto Clinico Humanitas
Rozzano, Milan, Italy Recruiting -
Ospedale Pederzoli
Peschiera del Garda, Verona, Italy Recruiting -
San Raffele Vita Salute University Hospital
Milan, Italy Recruiting -
Chirurgia Generale e del Pancreas
Verona, Italy Recruiting
Study contacts
- Study coordinator: Salvatore Paiella, MD, PhD
- Email: salvatore.paiella@univr.it
- Phone: 00390458126009
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating genetic risk and screening for prostate cancer
This study is testing if prostate MRIs can help men at high genetic risk for prostate cancer find aggressive forms of the disease earlier.
-
Developing a liquid biopsy protocol for cancer research at Princess Margaret
This study is trying to create a simple way to collect blood samples from cancer patients to see if analyzing certain molecules in their blood can help doctors understand their cancer better and track how it changes over time.
-
Liquid biopsy biomarkers to detect and monitor pancreatic cancer
Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.
-
Platform for women with BRCA1 or BRCA2 mutations in Italy
This project will try to collect clinical and follow-up data from women in Italy who carry pathogenic BRCA1 or BRCA2 mutations to build a national registry that can guide prevention and care.
-
Hormone replacement after risk-reducing salpingo-oophorectomy
This trial will test whether adding a short educational video to usual counseling helps premenopausal people with BRCA1 or BRCA2 mutations who are planning risk-reducing salpingo-oophorectomy decide about hormone replacement therapy.
-
Testing axatilimab with olaparib for advanced HER2-negative breast cancer with specific gene mutations
This study is testing a new drug called axatilimab combined with olaparib to see if it helps people with advanced HER2-negative breast cancer who have specific gene mutations.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.